Nucleai Announces Participation in United States and Canadian Academy of Pathology (USCAP) Annual Meeting 2019

TEL AVIV, Israel and NATIONAL HARBOR, Maryland, March 12, 2019 /PRNewswire/ -- Nucleai, an AI company working with and for pathologists to improve diagnoses, announced it will be exhibiting at the 2019 United States and Canadian Academy of Pathology (USCAP), held at National Harbor, Maryland from March 16-21, 2019.

USCAP's annual meeting, organized by the United States and Canadian Academy of Pathology, is the largest pathology meeting in the US. With over 40 divisions of pathology covered in specialized committee meetings, seminars, presentations, short courses and more, the event provides the latest news and innovations in the field.

Nucleai is making cancer diagnostics more accurate, accessible and efficient through AI-based analysis of biopsies. With decades of cumulative experience in AI, machine learning and machine vision, the company's team has created clinically validated products to tackle the industry's greatest problem — the growing demand for biopsies alongside a shortage of pathologists. Nucleai offers a full line of products powered by AI that analyze biopsies in the GI, breast and prostate categories. With the company's easily integrated and cloud-based solution, pathologists benefit from increased efficiency and accuracy and the ability to suggest the most relevant path for patients.

"Nucleai is thrilled to participate in this event which brings together the greatest minds in the field of pathology," said Avi Veidman, CEO and founder of Nucleai. "USCAP's dedication to create a gold standard in advancing skills available to pathologists reflects our mission to improve people's lives and we are excited to contribute our complete solution to the field."

At the conference, the company will be unveiling its latest research exploring the potential of digital image analysis (DIA) to aid in the identification of HP in H&E stained pathological tissue specimens; the research can be found at Poster Board 232, March 19th, Exhibit Hall H, 1:00 - 4:30 PM. In addition, Nucleai will also be exhibiting a poster demonstrating the capability of artificial intelligence based digital image analysis (AIIA) to successfully categorize colonic polyps; this research can be found at Poster Board 70, March 20th, Exhibit Hall C, 9:30 -12:00 PM.

The pathology conference attracts leaders in the field from different countries and specialties, making the 108^th Annual Meeting a prime networking opportunity for pathologists, investors, start-up founders and researchers to connect and benefit from modern pathology innovations.

If you would like to schedule a meeting with Nucleai at USCAP, please contact Arnon Horev, Chief Business Officer, at [email protected], or swing by booth 805 during the conference. 

About Nucleai
Founded in 2017, Nucleai is an AI healthcare startup in the field of pathology making biopsy diagnoses accurate, efficient and accessible to improve the current standard of care in the field of oncology and to expedite the development of novel cancer treatments. Led by a highly skilled team of artificial intelligence experts and leading clinicians, Nucleai improves cancer diagnostics using machine learning, deep learning and machine vision technologies. Nucleai is the only company to provide a comprehensive suite of solutions for biopsies relating to gastro, breast and prostate analysis. Nucleai is supported by leading pathologists in Israel and in the US and has raised $5M in funding to date. For more information, visit https://www.nucleaimd.com/. 

Media Contact
Orit Yogev
Headline Media
[email protected]
+1 516 725 9202

SOURCE Nucleai

Related Links

https://www.nucleaimd.com/